Urogenital congenital anomalies

• 1950Cortisone acetate approved (FDA)
• 1952Hydrocortisone approved (FDA)
• 1955Fludrocortisone acetate approved (FDA)
• 1955Prednisone approved (FDA)
• 1955Prednisolone approved (FDA)
• 1958Dexamethasone approved (FDA)
• 1959Dexamethasone phosphoric acid approved (FDA)
• 1972Testosterone approved (FDA)
• 1976Somatropin approved (FDA)
• 2014Testosterone undecanoate approved (FDA)

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

Urogenital congenital anomalies are a spectrum. Surgery can cure defined structural problems such as hypospadias and undescended testis, but severe kidney or urinary tract malformations often leave lasting damage and are managed rather than truly cured. Over time, outcomes have steadily improved through earlier diagnosis, refined surgical techniques, and coordinated pediatric care. The first milestone in this progress was the approval of cortisone acetate in 1950, which opened up managing related hormonal complications. Yet no universal prevention exists, and many children continue to need lifelong follow-up. The direction is positive, but many uncertainties remain about how to close the gap between curable and chronic forms. This is not a curable disease for everyone; the path forward depends on both treatment access and continued research.

How many children are affected each year?

Exact global counts are not included in this atlas entry, but urogenital anomalies are among the most common birth defects seen worldwide. Rates vary widely because many forms are mild and reported inconsistently.

Can surgery restore normal function?

For hypospadias and undescended testis, surgical repair often achieves a functional, cosmetic cure. For more severe kidney or bladder malformations, surgery improves drainage and preserves remaining function but cannot replace damaged tissue.

Does the condition progress after treatment?

Mild structural anomalies usually resolve after corrective surgery. Severe malformations like posterior urethral valves can slowly damage kidneys over decades, and some children later advance to kidney failure, which is why long-term monitoring is necessary.

Will a transplant or long-term dialysis likely needed?

Children whose malformations cause progressive chronic kidney disease may eventually need dialysis or a transplant, but most of the affected do not go that far. New surgical approaches and medical therapies aim to delay complications, though no universal guarantee exists.

What is being studied now in trails?

There are 145 active trials, with 123 started in the past five years and 12 in late-stage phase 3. Research focuses heavily on low-risk surgical techniques, fetal intervention, and prenatal markers to predict severe kidney disease risk before birth.